We hold innovative biomimetic nanoparticle platform technology that can deliver drugs effectively. We have Alzheimer’s new drug pipelines that enables amyloid beta clearance and ameliorates neuroinflammation mediated by microglia.
Our MEPS-X platform also enables in-depth mechanism studies and more efficient evaluation of our new drug pipelines.